Pantoprazole: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Full Generic Medicine Info

Dosage/Direction for Use Administration Contraindications Special Precautions Adverse Reactions Drug Interactions Food Interaction Lab Interference Action Storage CIMS Class ATC Classification

This information is not country-specific. Please refer to the India prescribing information.

Generic Medicine Info

Administration

Controlled-release: Should be taken on an empty stomach. Take 1 hr before meals. Swallow whole, do not chew/crush.
Normal release: May be taken with or without food.

Contraindications

Concomitant use with rilpivirine and atazanavir.

Special Precautions

Patient with gastric malignancy, risk factors for reduced vitamin B₁₂ absorption or at risk for osteoporosis. CYP2C19 poor metabolisers. Hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause dizziness or visual disturbances, if affected, do not drive or operate machinery. Monitoring Parameters Monitor bone loss, fractures, Clostridium difficile-associated diarrhoea (CDAD), serum Mg (at baseline and periodically), serum gastrin level concentrations.

Adverse Reactions

Significant: Hypomagnesaemia, cutaneous lupus erythematosus, SLE, osteoporosis-related fractures, fundic gland polyp, carcinoma, Clostridium difficile-associated diarrhoea, interstitial nephritis, Vitamin B₁₂ deficiency (long-term therapy), gastrointestinal infection (e.g. salmonella, Campylobacter). Gastrointestinal disorders: Nausea, vomiting, diarrhoea, constipation, flatulence, abdominal pain, dyspepsia, dry mouth. General disorders and administration site conditions: Asthenia, fatigue, malaise. Hepatobiliary disorders: Increased liver enzymes. Immune system disorders: Urticaria. Metabolism and nutrition disorders: Peripheral oedema. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia. Nervous system disorders: Headache, dizziness, vertigo. Psychiatric disorders: Insomnia. Reproductive system and breast disorders: Gynaecomastia. Skin and subcutaneous tissue disorders: Rash, pruritus.

Drug Interactions

May decrease plasma concentrations of rilpivirine and atazanavir. Increased risk of hypomagnesaemia with diuretics. Increased risk of digoxin-induced cardiotoxic effects. May increase INR and prothrombin time of warfarin. May increase plasma concentration of methotrexate. May decrease absorption of itraconazole, ketoconazole, posaconazole, erlotinib. May diminish the therapeutic effect of clopidogrel.

CIMS Class

Antacids, Antireflux Agents & Antiulcerants

ATC Classification

A02BC02 - pantoprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).

Disclaimer: This information is independently developed by CIMS based on pantoprazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 CIMS. All rights reserved. Powered by CIMSAsia.com